Gilead Sciences, Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the sale, the executive vice president now owns 102,988 shares in the company, valued at approximately $7,318,327.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Gilead Sciences, Inc. (GILD) traded down 1.95% during trading on Thursday, reaching $69.48. 7,989,034 shares of the company were exchanged. The firm has a market cap of $90.79 billion, a price-to-earnings ratio of 7.34 and a beta of 1.21. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $88.85. The firm has a 50-day moving average of $66.03 and a 200-day moving average of $68.95.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.18 by $0.02. The firm had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.66 billion. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. On average, equities analysts forecast that Gilead Sciences, Inc. will post $8.35 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 29th. Investors of record on Friday, June 16th were issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.99%. The ex-dividend date was Wednesday, June 14th. Gilead Sciences’s dividend payout ratio is currently 21.99%.

ILLEGAL ACTIVITY WARNING: “Gregg H. Alton Sells 5,000 Shares of Gilead Sciences, Inc. (GILD) Stock” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/06/gregg-h-alton-sells-5000-shares-of-gilead-sciences-inc-gild-stock.html.

Several research firms recently weighed in on GILD. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 price objective on the stock in a research note on Monday, June 26th. J P Morgan Chase & Co reiterated an “overweight” rating and set a $82.00 price objective on shares of Gilead Sciences in a research note on Tuesday. Jefferies Group LLC reiterated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research note on Tuesday. Cowen and Company reiterated an “outperform” rating and set a $90.00 price objective on shares of Gilead Sciences in a research note on Wednesday. Finally, Leerink Swann reiterated a “market perform” rating on shares of Gilead Sciences in a research note on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, fifteen have given a buy rating and two have assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $80.52.

A number of hedge funds and other institutional investors have recently modified their holdings of GILD. Bank of New York Mellon Corp boosted its position in shares of Gilead Sciences by 9.8% in the first quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock worth $2,076,368,000 after buying an additional 2,727,063 shares in the last quarter. Parnassus Investments CA boosted its position in shares of Gilead Sciences by 37.4% in the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after buying an additional 4,556,901 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Gilead Sciences by 2.2% in the fourth quarter. Franklin Resources Inc. now owns 14,317,385 shares of the biopharmaceutical company’s stock worth $1,025,373,000 after buying an additional 313,703 shares in the last quarter. Norges Bank purchased a new position in shares of Gilead Sciences during the fourth quarter worth about $997,048,000. Finally, APG Asset Management N.V. boosted its position in shares of Gilead Sciences by 16.7% in the first quarter. APG Asset Management N.V. now owns 5,923,426 shares of the biopharmaceutical company’s stock worth $402,319,000 after buying an additional 849,741 shares in the last quarter. Hedge funds and other institutional investors own 73.99% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.